Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients

Masaki Shiota1 | Naoki Terada2 | Toshihiro Saito3 | Akira Yokomizo4 | Naoki Kohei5 | Takayuki Goto6 | Sadafumi Kawamura7 | Yasuhiro Hashimoto8 | Atsushi Takahashi9 | Takahiro Kimura10 | Ken-ichi Tabata11 | Ryotaro Tomida12 | Kohei Hashimoto13 | Toshihiro Sakurai14 | Toru Shimazu15 | Shinichi Sakamoto16 | Manabu Kaniyama17 | Nobumichi Tanaka18 | Koji Mitsuzuka19 | Takuma Kato20 | Shintaro Narita21 | Hiroaki Yasumoto22 | Shogo Teraoka23 | Masashi Kato24 | Takahiro Osawa25 | Yoshiyuki Nagumo26 | Hiroaki Matsumoto27 | Hideki Enokida28 | Takayuki Sugiyama29 | Kentaro Kuroiwa30 | Takahiro Inoue6 | Takashi Mizowaki31 | Toshiyuki Kamoto2 | Takahiro Kojima26 | Hiroshi Kitamura32 | Mikio Sugimoto20 | Hiroyuki Nishiyama26 | Masatoshi Eto1 | Japanese Urological Oncology Group (JUOG)

1Department of Urology, Kyushu University, Fukuoka, Japan
2Department of Urology, Miyazaki University, Miyazaki, Japan
3Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan
4Department of Urology, Harasanshin Hospital, Fukuoka, Japan
5Department of Urology, Shizuoka General Hospital, Shizuoka, Japan
6Department of Urology, Kyoto University, Kyoto, Japan
7Department of Urology, Miyagi Cancer Center, Natori, Japan
8Department of Urology, Hirosaki University, Hirosaki, Japan
9Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan
10Department of Urology, Jikei University, Tokyo, Japan
11Department of Urology, Kitasato University, Sagamihara, Japan
12Department of Urology, Shikoku Cancer Center, Matsuyama, Japan
13Department of Urology, Sapporo Medical University, Sapporo, Japan
14Department of Urology, Yamagata University, Yamagata, Japan
15Department of Urology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, Japan
16Department of Urology, Chiba University, Chiba, Japan
17Department of Urology, University of Yamanashi Hospital, Chuo, Japan
18Department of Urology, Nara Medical University, Kashihara, Japan
19Department of Urology, Tohoku University, Sendai, Japan
20Department of Urology, Kagawa University, Kagawa, Japan
21Department of Urology, Akita University, Akita, Japan
22Department of Urology, Shimane University, Izumo, Japan
23Department of Urology, Tottori University, Yonago, Japan
24Department of Urology, Nagoya University, Nagoya, Japan

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
1 | INTRODUCTION

The CHAARTED and STAMPEDE (arm C) trials of docetaxel chemotherapy with androgen-deprivation therapy (ADT) showed beneficial effects on both progression-free survival (PFS) and overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (HSPC).\textsuperscript{1-3} Since then, survival benefit has also been demonstrated with the cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17) inhibitor abiraterone (LATITUDE and STAMPEDE [arm G] trials) and the novel antiandrogens enzalutamide (ENZAMET trial) and apalutamide (TITAN trial) with ADT.\textsuperscript{4-7} Two randomized trials, HORRAD and STAMPEDE (arm H), have additionally shown a potential survival benefit with prostate-targeted radiotherapy for patients with low metastatic burden HSPC.\textsuperscript{8,9} Based on these findings, novel therapeutic modalities combined with ADT are now recommended therapeutic options for metastatic HSPC.\textsuperscript{10}

The survival benefits of these novel therapies differ according to tumor aggressiveness, burden, and spread. In the CHAARTED trial, upfront docetaxel chemotherapy with ADT significantly prolonged the survival of patients with high-volume disease (defined as visceral metastasis or ≥4 bone metastases beyond the vertebrae and pelvis), but it is not yet known whether the same regimen increases the survival of patients with low-volume disease.\textsuperscript{11} In this regard, although the STAMPEDE (arm C) trial suggested comparable survival benefits for patients with low- and high-volume disease, the effects did not achieve statistical significance.\textsuperscript{12} Local radiotherapy has been shown to benefit patients with oligometastatic, but not high-volume metastatic, HSPC. The STOPCAP meta-analysis of the HORRAD and
The study was approved by the institutional review board of each study in Japan to investigate prognostic factors differentially associated with PFS and OS in patients with de novo metastatic HSPC. Here, we report the results of a multi-institutional study in Japan to investigate prognostic factors differentially associated with PFS and OS in patients with de novo metastatic HSPC with low- or high-metastatic burden.

2 | MATERIALS AND METHODS

2.1 | Patients

This study retrospectively enrolled patients who were newly diagnosed with de novo metastatic prostate cancer between 2008 and 2017 at 30 institutions, mainly academic hospital and cancer centers, participating in the Japanese Urological Oncology Group (JUOG). The study was approved by the institutional review board of each institute. All patients were pathologically diagnosed with adenocarcinoma of the prostate, and distant metastasis was detected by computed tomography and bone scans performed at the time of diagnosis. Of the 2829 patients with metastatic prostate cancer described in our previous report, we excluded 379 patients with (i) unknown number of bone metastases, (ii) unknown M1 sub-stage, (iii) unknown/undetermined Gleason grade group, or pathological diagnosis other than adenocarcinoma, (iv) initial treatment (eg, upfront docetaxel and upfront ARPI) other than castration monotherapy or combined androgen blockade (CAB), or (vi) unknown prognosis. In total, data were analyzed for 2450 patients.

2.2 | Methods

Demographic, clinicopathological, and survival data were obtained from medical records. Clinical staging was determined by the unified TNM criteria. Gleason grade categories at initial diagnosis were evaluated as <3 + 4 = 7 (I); 3 + 4 (II); 4 + 3 (III); 4 + 4 (IV); or 9-10 (V). Gleason scores 3 + 5 and 5 + 3 were included in category IV, according to a previous report. Patients were dichotomized into low-burden (lymph node metastasis and/or <4 bone metastases without visceral metastasis) and high-burden (≥4 bone metastases and/or visceral metastasis) groups. Hormone therapy was given as castration monotherapy (surgical or medical castration) or CAB (surgical or medical castration plus a first-generation nonsteroidal antiandrogen [bicalutamide and flutamide]), PFS was calculated from the date of diagnosis to the date of progression, defined as PSA levels increased by 25% from nadir and higher than 2.0 ng/mL, and OS was calculated as the date of diagnosis to the date of death due to any cause. Surviving patients without disease progression were censored at the last follow-up visit.

2.3 | Statistical analysis

All analyses were carried out using JMP13 software (SAS Institute, Cary, NC, USA). Continuous and categorical data were analyzed by Wilcoxon rank sum and Pearson’s chi squared tests, respectively. Survival analyses were conducted by the Kaplan-Meier method and log-rank test. A Cox proportional hazards model was used to estimate hazard ratios (HR). The differential prognostic value of clinicopathological parameters was investigated through interaction tests. All P values were two-sided; P < .05 was considered significant.

3 | RESULTS

Of the 2450 men retrospectively analyzed, 841 (34.3%) and 1609 (65.7%) were classified as having low- and high-burden disease, respectively. When patient characteristics were compared, pain level, PSA value, percentage of biopsy positive cores, biopsy Gleason grade group, T-stage, N-stage, M-stage, and extent of disease (EOD) score were all less favorable for patients in the high-burden compared with the low-burden group (Table 1). Most patients (86.7%) were treated with CAB, and a minority (n = 342; 14.0%) received local radiotherapy. Among the patients with lung (n = 268) or liver (n = 33) metastasis, 198 (73.9%) and 27 (81.8%), respectively, also had bone metastasis. None of the patients had concomitant lung and liver metastases.

During follow up, 424 (50.4%) and 231 (27.5%) patients experienced disease progression and death due to any cause in the low-burden group while 1109 (68.9%) and 661 (41.1%) patients experienced disease progression and death due to any cause in the high-burden group, respectively. Median follow-up time for men alive at the date of censor was 39.2 months (interquartile range [IQR], 22.1-66.8 months). Median PFS and OS were 21.3 months (95% confidence interval [CI] 20.1-23.1 months) and 66.4 months, respectively (P < .0001; Figure 1A), and the median OS was 103.2 months (95% CI 70.4-82.0 months), respectively. In the low- and high-burden groups, the median PFS was 44.5 months (95% CI 36.9-51.9 months) and 22.1-66.8 months. Median PFS and OS were 21.3 months (95% CI 20.1-23.1 months) and 66.4 months, respectively (P < .0001; Figure 1A), and the median OS was 103.2 months (95% CI 70.4-82.0 months), respectively (P < .0001; Figure 1B).

Next, we analyzed the prognostic value of various parameters for PFS. PFS was significantly associated with age, PSA value, percentage of biopsy positive cores, biopsy Gleason grade group, T-stage, and N-stage in the low-burden group, and with pain, PSA value, biopsy Gleason grade group, T-stage, N-stage, and therapeutic modality in the high-burden group (Table 2). When
interaction P values as prognostic value of clinicopathological parameters were calculated, percentage of biopsy positive core, biopsy Gleason grade group, T-stage, and N-stage were identified to be differentially prognostic for PFS. Among the patients with low metastatic burden, M1a was associated with worse PFS than was M1b (HR, 1.39; 95% CI, 1.11-1.73; P = .0037), whereas the reverse was true for the all-patient group (HR, 0.77; 95% CI, 0.63-0.94; P = .0093) (Table 2). In the high-burden group, M1c (lung metastasis) was associated with better PFS than was M1b (HR, 0.65; 95% CI, 0.55-0.77; P < .0001), whereas PFS was comparable between patients with lung metastasis and M1b within the all-patient group (HR, 0.86; 95% CI, 0.73-1.02; P = .077; Table 2). High EOD score and liver metastasis were unfavorable prognostic factors for PFS in both the high-burden and all-patient groups (Table 2).

We analyzed the prognostic factors for OS according to metastatic burden in the same manner. OS was significantly associated with pain, percentage of biopsy positive cores, biopsy Gleason grade group, T-stage, and N-stage in the low-burden group, and with age, biopsy Gleason grade group, and T-stage in the high-burden group (Table 3). When interaction P values as prognostic value of clinicopathological parameters were calculated, only T-stage was identified to be differentially prognostic for OS. OS was comparable between the M1a and M1b subgroups of patients with low metastatic burden.

TABLE 1 Patient characteristics stratified by metastatic burden

| Variable                      | Metastasis burden |         |         | P-value |
|-------------------------------|-------------------|---------|---------|---------|
|                               | Low burden (n = 841) | High burden (n = 1609) |
| Age at diagnosis, years (IQR) | 73 (67-79)        | 73 (66-78)        | .084    |
| NA                            | 3                 | 5        |         |         |
| Pain                          |                   |         |         |         |
| Absence                       | 758 (91.7%)       | 1150 (72.5%) | <.0001* |
| Presence                      | 69 (8.3%)         | 436 (27.5%)  | <.0001* |
| NA                            | 14                | 23       |         |         |
| PSA value at diagnosis, ng/mL (IQR) | 80.4 (26.1-249) | 365 (105-1078) | <.0001* |
| NA                            | 5                 | 8        |         |         |
| Percentage of biopsy positive core, n (%) | ≤66% | 268 (33.1%) | 371 (23.9%)  | <.0001* |
| >66%                          | 542 (66.9%)       | 1184 (76.1%) | <.0001* |
| NA                            | 31                | 54       |         |         |
| Biopsy Gleason grade group, n (%) |         |         |         | <.0015* |
| Group ≤ IV                    | 348 (41.4%)       | 561 (34.9%)      |         |
| Group V                       | 493 (58.6%)       | 1048 (65.1%)     | <.0001* |
| Clinical T-stage, n (%)       |                   |         |         |         |
| T1/2                          | 169 (20.5%)       | 218 (13.9%)      |         |
| T3                            | 465 (56.3%)       | 815 (52.0%)      | <.0001* |
| T4                            | 192 (23.2%)       | 535 (34.1%)      | <.0001* |
| NA                            | 15                | 41       |         |         |
| Clinical N-stage, n (%)       |                   |         |         |         |
| N0                            | 342 (41.0%)       | 589 (36.9%)      |         |
| N1                            | 492 (59.0%)       | 1009 (63.1%)     | .046*   |
| NA                            | 7                 | 11       |         |         |
| Clinical M-stage, n (%)       |                   |         |         |         |
| M1a                           | 188 (22.4%)       | –       |         | <.0001* |
| M1b                           | 653 (77.6%)       | 1308 (81.3%)     |         |
| M1c (lung)                    | –                 | 268 (16.7%)      |         |
| M1c (liver)                   | –                 | 33 (2.1%)       | <.0001* |
| EOD score, n (%)              |                   |         |         |         |
| EOD1                          | 653 (100%)        | 318 (20.7%)      |         |
| EOD2                          | –                 | 623 (40.6%)      |         |
| EOD3                          | –                 | 433 (28.2%)      |         |
| EOD4                          | –                 | 159 (10.4%)      | <.0001* |
| Therapeutic modality, n (%)   |                   |         |         |         |
| Castration                    | 125 (14.9%)       | 201 (12.5%)      | .10     |
| CAB                           | 716 (85.1%)       | 1408 (87.5%)     |         |

Abbreviations: CAB, combined androgen blockade; EOD, extent of disease; IQR, interquartile range; PSA, prostate-specific antigen. *Statistically significant.
metastatic burden (HR, 1.27; 95% CI, 0.93-1.74; P = .13), whereas the M1a subgroup had better OS than M1b when all patients were assessed (HR, 0.73; 95% CI, 0.55-0.97; P = .030) (Table 3). As noted for PFS, OS was better for patients with lung metastasis than with M1b in the high-burden group (HR, 0.66; 95% CI, 0.52-0.83; P = .0004), but it was comparable in the M1a and M1b subgroups of all patients (HR, 0.83; 95% CI, 0.66-1.05; P = .13) (Table 3). High EOD score and liver metastasis were unfavorable prognostic factors for OS in both the high-burden and all-patient groups, as noted for PFS (Table 3).

Kaplan-Meier survival curves confirmed the differential prognostic values of percentage of biopsy positive cores, biopsy Gleason grade group, T-stage, N-stage, and metastatic sites in patients with low and high metastatic burden (Figures 2 and 3).

### TABLE 2 Associations between clinicopathological parameters and progression-free survival

| Variable                        | Low burden       |                      | High burden      |                      | Interaction | P-value |
|---------------------------------|------------------|----------------------|------------------|----------------------|-------------|---------|
|                                 | HR 95% CI        | P-value              | HR 95% CI        | P-value              |             |         |
| Age at diagnosis, years         |                  |                      |                  |                      |             |         |
| ≤70                             | Ref  - -         | - -                  | Ref  - -         | - -                  | .071        |         |
| >70                             | 0.75  0.62-0.91  | .0037                | 0.93  0.82-1.04  | .21                  |             |         |
| Pain                            |                  |                      |                  |                      |             |         |
| Absence                         | Ref  - -         | - -                  | Ref  - -         | - -                  | .42         |         |
| Presence                        | 1.10  0.79-1.54  | .57                  | 1.24  1.09-1.41  | .0009                | <.0001      |         |
| PSA value at diagnosis, ng/mL   |                  |                      |                  |                      |             |         |
| ≤100                            | Ref  - -         | - -                  | Ref  - -         | - -                  | .55         |         |
| >100, ≤500                      | 1.43  1.15-1.78  | .0012                | 1.21  1.03-1.43  | .022                | <.0001      |         |
| >500                            | 1.69  1.30-2.20  | <.0001               | 1.60  1.37-1.87  | <.0001               | <.0001      |         |
| Percentage of biopsy positive core |              |                      |                  |                      |             |         |
| ≤66%                            | Ref  - -         | - -                  | Ref  - -         | - -                  | <.0001      |         |
| >66%                            | 2.32  1.84-2.93  | <.0001               | 1.14  0.99-1.32  | .064                 |             |         |
| Biopsy Gleason grade group      |                  |                      |                  |                      |             |         |
| Group ≤ IV                      | Ref  - -         | - -                  | Ref  - -         | - -                  | .0071       |         |
| Group V                         | 2.23  1.89-2.88  | <.0001               | 1.57  1.38-1.79  | <.0001               | <.0001      |         |
| Clinical T-stage                |                  |                      |                  |                      |             |         |
| T1/2                            | Ref  - -         | - -                  | Ref  - -         | - -                  | .0005       |         |
| T3                              | 1.62  1.21-2.17  | .0012                | 1.06  0.88-1.28  | .06                  |             |         |
| T4                              | 3.31  2.42-4.54  | <.0001               | 1.50  1.24-1.83  | <.0001               | <.0001      |         |
| Clinical N-stage                |                  |                      |                  |                      |             |         |
| N0                              | Ref  - -         | - -                  | Ref  - -         | - -                  | .0028       |         |
| N1                              | 2.03  1.65-2.49  | <.0001               | 1.32  1.17-1.50  | <.0001               | <.0001      |         |
| Clinical M-stage                |                  |                      |                  |                      |             |         |
| M1a                             | 1.39  1.11-1.73  | .0037                | - - - -          | - - - -             |             |         |
| M1b                             | Ref  - -         | - -                  | Ref  - -         | - -                  |             |         |
| M1c (lung)                      | - - - -          | 0.65                 | 0.55-0.77        | <.0001               |             |         |
| M1c (liver)                     | - - - -          | 1.41                 | 0.94-2.12        | .095                 |             |         |
| EOD score                       |                  |                      |                  |                      |             |         |
| EOD1                            | - - - -          | Ref                  | - - - -          | - - - -             |             |         |
| EOD2                            | - - - -          | 1.71                 | 1.43-2.04        | <.0001               |             |         |
| EOD3                            | - - - -          | 2.22                 | 1.85-2.68        | <.0001               |             |         |
| EOD4                            | - - - -          | 3.63                 | 2.89-4.55        | <.0001               |             |         |
| Therapeutic modality            |                  |                      |                  |                      |             |         |
| Castration                      | 0.78  0.60-1.02  | .069                 | 0.83  0.69-0.977 | .046                 | .97         |         |
| CAB                             |                  |                      |                  |                      |             |         |

Abbreviations: CAB, combined androgen blockade; CI, confidence interval; EOD, extent of disease; HR, hazard ratio; PSA, prostate-specific antigen. *Statistically significant.
TABLE 3  Associations between clinicopathological parameters and overall survival

| Variable                      | Low burden |                     | High burden |                     | Interaction |
|-------------------------------|------------|---------------------|-------------|---------------------|-------------|
|                               | HR  | 95% CI  | P-value | HR  | 95% CI  | P-value | P-value |
| Age at diagnosis, years       |     |         |         |     |         |         |         |         |
| ≤70                           | Ref | –       | –       | Ref | –       | –       | .85     |
| >70                           | 1.16| 0.89-1.52| .27     | 1.18| 1.01-1.37| .040*   |
| Pain                          |     |         |         |     |         |         |         |         |
| Absence                       | Ref | –       | –       | Ref | –       | –       | .14     |
| Presence                      | 1.54| 1.02-2.31| .039*   | 1.10| 0.93-1.31| .25     |
| PSA value at diagnosis, ng/mL |     |         |         |     |         |         |         |         |
| ≤100                          | Ref | –       | –       | Ref | –       | –       | .20     |
| >100, ≤500                    | 1.20| 0.90-1.61| .22     | 0.87| 0.71-1.07| .20     |
| >500                          | 1.21| 0.85-1.74| .29     | 1.03| 0.85-1.25| .77     |
| Percentage of biopsy positive core |     |         |         |     |         |         |         |         |
| ≤66%                          | Ref | –       | –       | Ref | –       | –       | .091    |
| >66%                          | 1.57| 1.16-2.11| .0032*  | 1.14| 0.95-1.37| .17     |
| Biopsy Gleason grade group    |     |         |         |     |         |         |         |         |
| Group ≤ IV                    | Ref | –       | –       | Ref | –       | –       | .22     |
| Group V                       | 1.97| 1.48-2.62| <.0001* | 1.57| 1.33-1.86| <.0001* |
| Clinical T-stage              |     |         |         |     |         |         |         |         |
| T1/2                          | Ref | –       | –       | Ref | –       | –       | .021*   |
| T3                            | 1.25| 0.84-1.87| .27     | 1.02| 0.80-1.30| .88     |
| T4                            | 2.50| 1.63-3.82| <.0001* | 1.33| 1.03-1.72| .026*   |
| Clinical N-stage              |     |         |         |     |         |         |         |         |
| N0                            | Ref | –       | –       | Ref | –       | –       | .17     |
| N1                            | 1.36| 1.04-1.78| .026*   | 1.08| 0.92-1.26| .36     |
| Clinical M-stage              |     |         |         |     |         |         |         |         |
| M1a                           | 1.27| 0.93-1.74| .13     | –   | –       | –       | –       |
| M1b                           | Ref | –       | –       | Ref | –       | –       | –       |
| M1c (lung)                    | –   | –       | –       | 0.66| 0.52-0.83| .0004*  |
| M1c (liver)                   | –   | –       | –       | 2.08| 1.33-3.26| .0013*  |
| EOD score                     |     |         |         |     |         |         |         |         |
| EOD1                          | –   | –       | –       | Ref | –       | –       | –       |
| EOD2                          | –   | –       | –       | 1.52| 1.19-1.93| .0007*  |
| EOD3                          | –   | –       | –       | 1.82| 1.42-2.34| <.0001* |
| EOD4                          | –   | –       | –       | 3.45| 2.61-4.58| <.0001* |
| Therapeutic modality          |     |         |         |     |         |         |         |         |
| Castration                    | Ref | –       | –       | Ref | –       | –       | .31     |
| CAB                           | 1.13| 0.74-1.72| .59     | 0.93| 0.72-1.19| .56     |

Abbreviations: CAB, combined androgen blockade; CI, confidence interval; EOD, extent of disease; HR, hazard ratio; PSA, prostate-specific antigen. *Statistically significant.

4 | DISCUSSION

The criteria used in this study are similar to that in CHAARTED criteria although metastasis beyond vertebrae and pelvis was not included. Accordingly, the discrimination ability for PFS and OS between low- and high-metastatic burden in this study was similar to those by CHAARTED criteria.18,19

To our knowledge, this is the first investigation of how the prognostic factors for PFS and OS in Japanese patients with metastatic HSPC is affected by the metastatic burden. We identified how the percentage of biopsy-positive cores, biopsy Gleason grade group, T-stage, and N-stage differentially impact on the prognosis between low and high burden. Those findings suggest that locoregional tumor burden and cancer malignant potential
FIGURE 2  Kaplan-Meier analysis of progression-free survival in men with metastatic prostate cancer stratified by clinicopathological factors. A-E, Patients with low and high metastatic burden stratified by percentage biopsy positive cores (A), biopsy Gleason grade group (B), clinical T-stage (C), clinical N-stage (D), and metastatic site (E).
FIGURE 3 Kaplan-Meier overall survival analysis of men with metastatic prostate cancer stratified by clinicopathological factors. A-E, Patients with low and high burden stratified by percentage of biopsy-positive cores (A), biopsy Gleason grade group (B), clinical T-stage (C), clinical N-stage (D), and metastatic site (E).
have relatively greater impact in patients with low burden, but less in patients with high burden. In addition, this study suggested that M1a was a possible unfavorable prognostic factor in low burden, suggesting that M1a diseases may be more aggressive than oligometastatic bone metastatic disease.

In the present study, high EOD score and liver metastasis, but not lung metastasis, were unfavorable prognostic factors in the all-patient group, consistent with previous reports, as well as in the high-burden group, whereas lung metastasis was associated with a favorable prognosis in the high-burden group. These findings are consistent with previous work suggesting that liver and lung metastases have distinct prognostic value for patients with metastatic prostate cancer. In the present study of mostly Japanese men, lung and liver metastases were observed in 13.2% and 1.3% of patients, respectively, which contrasts with the almost equivalent prevalence rates of 5.7% and 4.5%, respectively, among patients with stage IV prostate cancer in the USA (Surveillance, Epidemiology and End Results–Medicare database). These findings suggest the possibility that metastatic prostate cancer may differ biologically and clinically among patients of different races. Otherwise, the difference in the medical care system such as access to chest computed tomography scan may affect the prevalence rate of lung metastasis.

The present study demonstrates for the first time the differential prognostic value of metastatic sites and other factors in Japanese patients with high- and low-volume metastatic disease, respectively. The results of the present study suggest that patients with low-burden disease and locoregional risk factors such as high percentage of biopsy positive cores, high Gleason grade group, high T-stage (especially T4), and, possibly, N1 may be ideal candidates for local therapy. A subgroup analysis of the STAMPEDE trial found that local radiotherapy had a favorable effect on OS for the T4, Gleason score ≥8, and N1 patient subgroups, whereas patients with HSPC, regardless of metastatic burden, and are currently in clinical use. In contrast, upfront docetaxel chemotherapy and local radiotherapy are thought to be more suitable for patients with high- and low-volume metastatic disease, respectively. The results of the present study suggest that patients with low-burden disease and unfavorable prognostic factors may benefit more from therapies such as ARPI, whereas patients with high-burden disease and unfavorable prognostic factors may require more intensive therapies, such as docetaxel in combination with ARPI; notably, the latter combination is under investigation in the PEACE-I and ARASENS trials. The results of those studies will undoubtedly be valuable in developing novel therapeutic strategies for patients with metastatic HSPC who have differing metastatic burdens.

The present study has several limitations. First, the study design was retrospective. Second, the study cohort consisted mostly of Japanese patients, which may limit the applicability of the findings to other patient ethnicities. Third, the accrual period included the era before novel agents for hormone-refractory prostate cancer were introduced, and several of our patients died before abiraterone acetate, enzalutamide, radium-233, and cabazitaxel became available. However, all patients had access to docetaxel chemotherapies. Finally, most metastasis was diagnosed by imaging modalities only without biopsy, where accuracy of metastasis is dependent on the diagnostic ability of imaging.

5 CONCLUSION

In conclusion, the results of this study identified differential prognostic factors for patients with low- and high-metastatic burden HSPC. These findings have several potential clinical implications; for example, they may assist in providing more accurate prognoses of patients with metastatic HSPC, in identifying novel therapeutic strategies for patients with differing metastatic burden, and in identifying patients who may benefit from more or less intensive therapies.

ACKNOWLEDGMENT

We thank Anne M. O’Rourke, PhD, from Edanz Group (www.edanz editing.com/ac) for editing a draft of this manuscript.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

ORCID

Masaki Shiota https://orcid.org/0000-0002-3306-4858
Shinichi Sakamoto https://orcid.org/0000-0002-7508-7521
Takahiro Osawa https://orcid.org/0000-0003-4444-7958
Hiroaki Matsumoto https://orcid.org/0000-0003-0568-1258
Hideki Enokida https://orcid.org/0000-0002-3050-9700

REFERENCES

1. Shiota M, Eto M. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol. 2016;23:360-369.
2. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737-746.
3. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163-1177.
4. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360.
5. James ND, de Boon JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338-351.
6. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121-131.
7. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13-24.
8. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen
deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial. *Eur Urol*. 2019;75:410-418.
9. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *Lancet*. 2018;392:2353-2366.
10. Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: Management of metastatic castration-resistant prostate cancer in the era of precision oncology. *Eur Urol*. 2019;75:88-99.
11. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. *J Clin Oncol*. 2018;36:1080-1087.
12. Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone-sensitive prostate cancer: long-term survival results from the STAMPEDE trial. *Ann Oncol*. 2019;30:1992-2003.
13. Burdett S, Boevé LM, Ingleby FC, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis. *Eur Urol*. 2019;76:115-124.
14. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: Report of the advanced prostate cancer consensus conference 2019. *Eur Urol*. 2020;77:508-547.
15. Terada N, Mizowaki T, Saito T, et al. Potential effectiveness of local radiotherapy for extending survival and reducing urinary-related events in patients with de novo metastatic prostate cancer. *BJUI Compass*. 2020;1:165-173.
16. International Union Against Cancer. Urologic Tumors. Prostate. In: Sobin LH, Wittekind CH, eds. *TNM classification of malignant tumors*, 5th edn. New York, NY: John Wiley & Sons; 1997:170-173.
17. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. *Eur Urol*. 2016;69:428-435.
18. Shiota M, Namitome R, Kobyayashi T, et al. Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer. *Int J Urol*. 2019;26:426-428.
19. Okamoto T, Hatakewata S, Narita S, et al. Validation and development of the CHAARTED criteria in patients with hormone-naïve metastatic prostate cancer: A multi-institutional retrospective study in Japan. *Int J Urol*. 2020;27:90-91.
20. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. *Cancer*. 1988;61:195-202.
21. Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. *Eur Urol*. 2015;68:325-334.
22. Akamatsu S, Kubota M, Uozumi R, et al. Development and validation of a novel prognostic model for predicting overall survival in treatment-naive castration-sensitive metastatic prostate cancer. *Eur Urol Oncol*. 2019;2:320-328.
23. Shiota M. Editorial Comment to Validation and development of the CHAARTED criteria in patients with hormone-naïve metastatic prostate cancer: A multi-institutional retrospective study in Japan. *Int J Urol*. 2020;27:92.

How to cite this article: Shiota M, Terada N, Saito T, et al; Japanese Urological Oncology Group (JUOG). Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. *Cancer Sci*. 2021;112:1524-1533. [https://doi.org/10.1111/cas.14722](https://doi.org/10.1111/cas.14722)